Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms

Current Medical Research and Opinion

Volumn 26, Issue 10, 2010, Pages 2277-2285

  Serels, Scott R ^a   Toglia, Marc R ^b   Forero Schwanhaeuser, Sergio ^c   He, Weizhong ^d  

^a Bladder Control Center of Norwalk   (United States)

^b Urogynecology Associates of Philadelphia   (United States)

^c GLAXOSMITHKLINE   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Overactive bladder; Patient reported outcomes; Solifenacin; Symptom severity; Urgency

Indexed keywords

PLACEBO; SOLIFENACIN;

ADULT; AGED; ARTICLE; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; NAUSEA; NOCTURIA; OVERACTIVE BLADDER; POST HOC ANALYSIS; QUALITY OF LIFE; RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PLACEBOS; QUALITY OF LIFE; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE; URINATION; YOUNG ADULT;

EID: 77956744676     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.509582     Document Type: Article

References (22)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61:37-49
2. Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006;25:293
3. Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005;95:335-340
4. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-336
5. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50: 1306-1314
6. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-562
7. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740-763
8. Landis JR, Kaplan S, Swift S, et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004;171:752-756
9. Preik M, Albrecht D, O'Connell M, et al. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. BJU Int 2004;94:821-827
10. Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin 2006; 22:41-48
11. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002;18:177-184
12. Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079-1086
13. Karram MM, Toglia MR, Serels SR, et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009; 73:14-18
14. Toglia MR, Serels SR, Laramee C, et al. Solifenacin treatment in patients with overactive bladder improves patient-reported outcomes in the VESIcare efficacy and safety in patients with urgency study (VENUS). Obst Gynecol 2009; In press
15. Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005;174:604-607
16. Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int 2005;95:591-596
17. Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 2005;14:849-855
18. Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-2194
19. Coyne KS, Elinoff V, Gordon DA, et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract 2008;62:925-931
20. Abrams P, Artibani W, Gajewski JB, et al. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006;68:17-28
21. Freeman RM. How urgent is urgency? A review of current methods of assessment. Int Urogynecol J Pelvic Floor Dysfunct 2005;16:93-95
22. Starkman JS, Dmochowski RR. Urgency assessment in the evaluation of overactive bladder (OAB). Neurourol Urodyn 2008;27:13-21